The rapid increase in CRISPR-mediated cell and gene therapies in clinical trials over the past few years is a testimony to the promising future of next-generation medicine.
While improved technological prowess empowers the development of more CRISPR-edited therapies, supply-chain and manufacturing hurdles still pose significant barriers to clinical and commercialization timelines.
Watch this webinar to learn more about:
- The state of CRISPR cell and gene therapies
- Challenges in CRISPR therapy manufacturing
- A next-generation manufacturing facility